Associated Papers
Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.
Brand F et al.
Acta Neuropathologica, 2026
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection.
Shen PY et al.
Oncology Letters, 2025
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K et al.
Molecular Oncology, 2021
Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.
Wei Q et al.
Lung Cancer (amsterdam, Netherlands), 2020
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
Truini A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L et al.
Theranostics, 2019
Genotyping of EGFR Mutations from Bronchial Cytological Specimens in Slovakian Lung Cancer Patients.
Baluchova K et al.
Advances in Experimental Medicine and Biology, 2016
Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS et al.
Medicine, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Okamoto I et al.
Oncotarget, 2014
Melting curve analysis for mutations of EGFR and KRAS.
Furugaki K et al.
Anticancer Research, 2014
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2010
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.
Sonobe M et al.
British Journal of Cancer, 2005
NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.
Kauffmann-Guerrero D et al.
Respiration; International Review of Thoracic Diseases, 0